Peregrine Pharmaceuticals reported $16.92M in Cost of Sales for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Adamas Pharmaceuticals ADMS:US 576K 49K
Agenus AGEN:US $ 817K 150K
Amgen AMGN:US $ 1609M 28M
AstraZeneca AZN:LN 3824M 1631M
Biocryst Pharmaceuticals BCRX:US $ 0.62M 0.27M
Bristol Myers Squibb BMY:US $ 2291M 160M
Eli Lilly And LLY:US $ 1430.8M 522.4M
Flexion Therapeutics FLXN:US $ 3.73M 1.25M
GlaxoSmithKline GSK:LN 2822M 303M
Intrexon XON:US $ 15.45M 0.42M
Karyopharm Therapeutics KPTI:US $ 589K 549K
Kindred Biosciences KIN:US $ 639K 49K
MacroGenics MGNX:US 1.66M 1.64M
Mannkind MNKD:US $ 9.89M 0.04M
Merk MRK:US $ 3056M 14M
Novartis NOVN:VX SF 3848M 94M
Peregrine Pharmaceuticals PPHM:US $ 16.92M 2.44M
Repligen RGEN:US $ 75.5M 13.5M